Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

This clinical trial is testing a new treatment for children and young adults with aggressive brain tumors, including DIPG and high grade glioma with a specific genetic change (H3 K27M mutation). The treatment combines standard radiation therapy with a new medicine called selinexor, which may help stop cancer cells from growing and shrink tumors. Patients receive radiation for 5-7 weeks and take selinexor pills weekly during and after radiation for up to two years. The study will first find the safest dose of selinexor and then test how well it works. MRIs and follow-up visits help monitor progress. Researchers hope this treatment will improve outcomes for these difficult-to-treat brain tumors.

NOTE: Enrollment for DIPG and DMG has been discontinued. This study is only opened for patients with HGG without a H3 K27M mutation. 

Inclusion Criteria

Pre-Enrollment

1. Age: Patients must be 25 years old or younger.
2. Diagnosis: Must have a newly diagnosed high-grade glioma (HGG) that hasn’t spread.
3. Consent: A parent or guardian, or the patient, must sign a consent form.
4. Samples (non-DIPG tumours): Tumour samples from surgery or biopsy need to be submitted soon after the procedure (ideally within 5 days).

Main Enrollment

1. Age: Patients must be between 1 and 21 years old.
2. Diagnosis:
   • DIPG: Must meet specific imaging or biopsy criteria. CLOSED
   • HGG: Must be newly diagnosed, without certain genetic mutations. OPEN
3. Patients need to be in good overall health with normal lab results and no severe symptoms.
4. Enrollment must happen within 31 days of diagnosis or surgery.
5. A signed consent form is required.

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This study is to assess the effectiveness of a drug called Difluoromethylornithine (DFMO) in combination with etoposide for patients with neuroblastoma that has come back, or is not responidng to current treatment. DFMO is a medication taken by mouth. It is an blocker of ornithine decarboxylase, an enzyme involved with polyamine biosynthesis in the cancer cells, including neuroblastoma cells. 

Inclusion Criteria

• Patients less than 31 years of age 
• Diagnosis of neuroblastoma that has come back or is not responding to treatment 
• Patients can have active or no active disease at the time of study start
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This study is testing a new treatment for children with DIPG or DMG brain tumors who have recently finished radiation. The treatment combines a vaccine (rHSC-DIPGVax) with two medicines, BALSTILIMAB and ZALIFRELIMAB. The main goal is to see if this combination is safe and can be tolerated. Patients may join if they were diagnosed with DIPG or DMG and completed radiation about 6–10 weeks before entering the study.

Inclusion Criteria

• Participants must be 12 months - 18 years old with newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) 
• Must have measurable tumor on scans
• Body size (BSA) must be at least 0.35 m²
• Must be up and about at least 50% of waking hours 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

Go to Health Care Provider version

Centres

Study Description

This study is part of a larger research project. The goal is to see if a new treatment called zilovertamab vedotin is safe and works well for children and young adults whose cancer has come back (relapsed) or did not get better with treatment (refractory).

The study is for patients with B-ALL (a type of leukemia that starts in the bone marrow and blood), DLBCL or Burkitt lymphoma (fast-growing blood cancers that affect the lymph nodes or organs), neuroblastoma (a cancer that starts in nerve cells, usually in young children), or Ewing sarcoma (a cancer of the bones or nearby tissue, often in children and teens).

Inclusion Criteria

• Participant must have one of the following diagnoses:
  • Blood cancers: children with a type of leukemia called B-ALL and children with certain fast-growing lymphomas (DLBCL or Burkitt lymphoma) OR
  • Solid tumors: children with neuroblastoma or children with Ewing sarcoma

Other inclusion or exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This study is to test the safety of a drug called lurbinectedin in solid tumours that have come back (relapsed) or not responded to treatment (refractory). It is conducted in 2 parts, Phase 2 will further assess this drug in participants with Ewing sarcoma specifically.

Inclusion Criteria

• Participant must meet the following age requirements:
  • Phase 1 Part 1: participants must be ≥ 2 to < 18 years of age.
  • Phase 1 Part 2: participants must be ≥ 2 to ≤ 30 years of age.
  • Phase 2: participants must be ≥ 2 to ≤ 30 years of age.
• Participant has a confirmed solid tumor (For phase 2, Ewing Sarcoma)
• The participant is up and about for more than half their waking hours
• Participant meets all lab value requirements during the screening period
• Participant weighs at least 15kg
• Must not be pregnant (if applicable), and/or must be on an acceptable birth control method 
• Must sign informed consent and agree to attending all required study assessments 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team 

Go to Health Care Provider version

Centres

Study Description

This is a phase I/II trial that studies how well the treatments tiragolumab and atezolizumab work when given to children with tumours that have either come back (relapsed) or did not respond to therapy (refractory). These tumours must have a certain mutation, meaning the cancer cells are missing important genes called SMARCB1 and SMARCA4. Tiragolumab and atezolizumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Inclusion Criteria

Part A is now completed, Part B criteria now applies: 

• Participants must be between 1-18 years old for part A of this study. There is no upper age limit for part B
• Participants must have one of the following cancers, that has either come back (relapsed) or did not respond to previous treatment (refractory):
  • Renal medullary carcinoma
  • Malignant rhabdoid tumor (extra-CNS)
  • Atypical teratoid rhabdoid tumor (CNS)
  • Poorly differentiated chordoma
  • Epithelioid sarcoma
• Cancer must have the eligible mutation (SMARCB1 or SMARCA4)
• Participants must be up and about for at least half their waking hours
• Participants must meet all bloodwork criteria outlined for this study

Other inclusion and exclusion criteria may apply and will be discussed with you by your clinical team

Go to Health Care Provider version

Centres

Study Description

This is a study to find out whether a drug called olaparib (also called a PARP inhibitor) is safe and well tolerated when administered to children and adolescents with solid tumours or brain tumours, when they have come back or are not improving with treatment.

Inclusion Criteria

• Patients are ≥ 6 months to <18 years of age 
• Patients have a solid tumour or brain tumour that has come back (relapsed) or is not improving with treatment (refractory)  
• There is a gene change in the tumour or in the normal cells of the patient that can be called "homologous recombination repair gene mutation"
• The patient can swallow tablets
• Multiple other inclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

The purpose of this study is to see if the experimental drug DAY101 is safe and effective in treating recurrent or progressive (tumor that has come back or isn’t improving despite treatment) glioma or solid tumors in pediatric, adolescent and young adult patients. The drug will be given in the form of oral tablets.

Inclusion Criteria

• Age between 6 months to 25 years
• Patient must be diagnosed with low grade glioma or solid tumor, that isn’t improving despite treatment 
• The tumour must display a genetic change called a "RAF alteration"
• Patient must be able to swallow oral tablets
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team